Scholars Central

CommentaryPublished 11 Jan 2021

Point of view about biologic therapy in covid-19

Authors: Santos Castañeda, Julio Ancochea, Belén Atienza-Mateo, Miguel A González-Gay

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

COVID-19 (COronaVIrus Disease firstly reported in December 2019) is a complex and heterogeneous disease whose clinical spectrum ranges from asymptomatic cases or with mild symptoms to severe acute respiratory distress syndrome, with/without heart and kidney involvement, especially in people with comorbidities. Treatment we use today is quite empirical, depending on the severity of the disease, associated risk factors and access to medication. In severe cases, a combination of potent anti-cytokine monoclonal antibodies associated to low-dose dexamethasone and remdesivir and/or favipiravir is recommended. Here, we review the clinical evidence and indications of main biologic therapy in the treatment of COVID-19 patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalAsian Journal of Biomedical and Pharmaceutical Sciences
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Santos Castañeda”
  • BylineArticles whose byline prints “Julio Ancochea”
  • BylineArticles whose byline prints “Belén Atienza-Mateo”
  • BylineArticles whose byline prints “Miguel A González-Gay”